Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02815267 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne
A Phase 3 study, sponsored by Vyne Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 466
- Enrollment target
NCT02815267 is a Phase 3 study that has completed, run by Vyne Therapeutics. The registered enrollment target is 466 participants.
The verdict
NCT02815267, a Phase 3 study, has completed, sponsored by Vyne Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 466 participants
- Enrollment target
Study Summary
This is a Phase 3 study to evaluate the efficacy, safety and long-term safety of the topical administration of FMX-101, 4% minocycline foam for the treatment of moderate-to-severe acne vulgaris.
Interventions
- DRUG Vehicle Foam
- DRUG FMX-101, 4% minocycline foam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 466 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-10-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02815267
The ClinicalTrials.gov registry entry for NCT02815267 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 466 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vyne Therapeutics, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle Foam is the first listed.
NCT02815267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02815267 about?
NCT02815267 is a clinical study titled "A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne". This is a Phase 3 study to evaluate the efficacy, safety and long-term safety of the topical administration of FMX-101, 4% minocycline foam for the treatment of moderate-to-severe acne vulgaris.
What is the current status of trial NCT02815267?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 466 participants. The study started on 2016-05. Estimated completion is 2017-10-13.
What interventions are being tested in trial NCT02815267?
The interventions under investigation include: Vehicle Foam (DRUG), FMX-101, 4% minocycline foam (DRUG).
Who is sponsoring clinical trial NCT02815267?
This trial is sponsored by Vyne Therapeutics, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.